Injectable HIV Prevention Drug Faces Access Barriers Due to USAID Cuts, Experts Warn

Innovations in HIV prevention, particularly the injectable drug lenacapavir, offer a significant opportunity to drastically reduce new HIV infections worldwide. Experts convened at the Aids 2026 Conference in Rio de Janeiro, Brazil, to discuss these advancements, but voiced serious concerns that anticipated cuts to United States foreign aid, specifically through the United States Agency for International Development (USAID), will critically undermine access to these life-saving interventions. Lenacapavir represents a significant evolution in pre-exposure prophylaxis (PrEP), a highly effective method for preventing HIV transmission. While existing PrEP options include daily oral pills and bimonthly injections, lenacapavir requires only two injections annually. This simplified regimen is expected to improve adherence and, consequently, enhance its effectiveness, which, when taken consistently, has already been established at a remarkable 99% for preventing sexually transmitted HIV. The World Health Organization (WHO), a leading global health authority, officially recommended that governments prioritize expanded access to lenacapavir for HIV prevention approximately one year before the conference. This endorsement from the WHO underscored the drug's potential public health impact and signaled a global shift towards more advanced prevention strategies. However, the optimism surrounding these medical breakthroughs is tempered by a stark reality: a global decline in investment in HIV prevention efforts. This broader trend, coupled with specific reductions in US foreign aid, creates a critical gap between the availability of cutting-edge prevention tools and their equitable distribution to those who need them most. The implications are particularly severe for low- and middle-income countries, which often carry the highest burden of HIV and are heavily reliant on international assistance for essential healthcare services. The experts at the Aids 2026 Conference emphasized that without sustained and adequate funding, the full potential of innovations like lenacapavir cannot be realized, potentially reversing decades of progress in the fight against the HIV/AIDS epidemic. They urged for a recommitment to global health security and a reversal of current funding trends to ensure that advancements in HIV prevention reach all populations, moving closer to the ultimate goal of ending the HIV epidemic.